Incyte Investor Relations Material
Latest events
Q1 2025
Incyte
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Incyte Corporation
Access all reports
Incyte is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company develops next generation medicines across its three core therapeutic platforms: cancer immunology, epigenetics and targeting microRNAs. The company's epigenetics platform is focused on technologies that can reprogram adult cells to their embryonic state to make them fertile ground for drug discovery.
Key slides for Incyte Corporation
Q1 2025
Incyte Corporation
Q1 2025
Incyte Corporation
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
INCY
Country
🇺🇸 United States